Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD: Case 2
Monoclonal Antibodies in Relapsed Multiple Myeloma with Ola Landgren, MD, PhD
Case Scenario 2:
January 2015
- The patient is a 72-year old female who was diagnosed with ISS stage I multiple myeloma.
- She is an insulin dependent diabetic who is experiencing peripheral neuropathy.
- Her cytogenetics were classified as standard risk, bone marrow show 50% light chain restricted plasma cells.
- M-spike IgG lambda 2.5 g/dL,
- Performance status 1.
- She received treatment with lenalidomide (25 mg daily) and low-dose dexamethasone and obtains a very good partial response.
- After a year she decided to come off of lenalidomide therapy.
July 2016
- Six months after stopping therapy,patient had increasing fatigue and weakness.
- M-spike is now 0.8 g/dL.
- CT scan revealed several bone lesions.
- Patient was started on daratumumab, lenalidomide and dexamethasone
Related Videos
Related Content
Isa-Kd Stands Out Among Subsequent Regimens in Multiple Myeloma
April 4th 2024Article
During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.
Read More
